Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials

Journal of Stroke and Cerebrovascular Diseases

Volumn 24, Issue 12, 2015, Pages 2710-2719

  Chen, Junyu ^a   Zhuang, Xiaodong ^a   Long, Ming ^a   Su, Chen ^a   Wang, Lichun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

bleeding; Edoxaban; nonvalvular atrial fibrillation; stroke; systemic embolism; warfarin

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BODY MASS; CARDIOVASCULAR MORTALITY; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FACTOR XA INHIBITORS; HUMANS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; TREATMENT OUTCOME; WARFARIN;

EID: 84949727970     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2015.07.026     Document Type: Article

References (30)

1. M. Alam, S.J. Bandeali, S.A. Shahzad, and et al. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry Expert Rev Cardiovasc Ther 10 2012 283 291
2. C.E. Chiang, L. Naditch-Brule, J. Murin, and et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry Circ Arrhythm Electrophysiol 5 2012 632 639
3. Fang M.C., A.S. Go, Chang Y., and et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study J Am Coll Cardiol 58 2011 395 401
4. G.Y. Lip Atrial fibrillation and stroke prevention: brief observations on the last decade Expert Rev Cardiovasc Ther 12 2014 403 406
5. G.Y. Lip, L. Frison, J.L. Halperin, and et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score J Am Coll Cardiol 57 2011 173 180
6. P. Loewen, and K. Dahri Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules Ann Hematol 90 2011 1191 1200
7. D. Poli, E. Antonucci, E. Grifoni, and et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years J Am Coll Cardiol 54 2009 999 1002
8. V. Serebruany, Rao S.V., M.A. Silva, and et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications Eur Heart J 31 2010 227 235
9. W.N. Kernan, B. Ovbiagele, H.R. Black, and et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 45 2014 2160 2236
10. K.L. Furie, L.B. Goldstein, G.W. Albers, and et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association Stroke 43 2012 3442 3453
11. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation 130 2014 2071 2104
12. R.G. Hart, J.L. Halperin, L.A. Pearce, and et al. Lessons from the stroke prevention in atrial fibrillation trials Ann Intern Med 138 2003 831 838
13. G.Y. Lip, R. Nieuwlaat, R. Pisters, and et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
14. B.F. Gage, A.D. Waterman, W. Shannon, and et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
15. U.A. Flato, P.S. Rheder, H.P. Guimaraes, and et al. Spine subdural hematoma: a rare complication associated with vitamin K antagonist (VKA) Arq Bras Cardiol 92 2009 e1 e3
16. M.K. Kovac, L.B. Rakicevic, J.S. Kusic-Tisma, and et al. Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation J Thromb Thrombolysis 35 2013 90 94
17. T. Desmettre, E. Dehours, C.M. Samama, and et al. Reversal of vitamin K antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of prothrombin complex concentrate (PCC) in current clinical practice Crit Care 16 2012 R185
18. R. Shameem, and J. Ansell Disadvantages of VKA and requirements for novel anticoagulants Best Pract Res Clin Haematol 26 2013 103 114
19. H. Heidbuchel, P. Verhamme, M. Alings, and et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
20. T. Yamashita, Y. Koretsune, M. Yasaka, and et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation Circ J 76 2012 1840 1847
21. N. Chung, H.K. Jeon, L.M. Lien, and et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation Thromb Haemost 105 2011 535 544
22. J.I. Weitz, S.J. Connolly, I. Patel, and et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Thromb Haemost 104 2010 633 641
23. R.P. Giugliano, C.T. Ruff, E. Braunwald, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
24. H.R. Buller, H. Decousus, M.A. Grosso, and et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 2013 1406 1415
25. H. Zahir, N. Matsushima, A.B. Halim, and et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects Thromb Haemost 108 2012 166 175
26. G. Renda, and R. De Caterina The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 59 2013 53 62
27. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
28. J. Zikria, and J. Ansell Oral anticoagulation with factor Xa and thrombin inhibitors: is there an alternative to warfarin? Discov Med 8 2009 196 203
29. S.S. Adam, J.R. McDuffie, T.L. Ortel, and et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Ann Intern Med 157 2012 796 807
30. Li S., Liu B., Xu D., and et al. Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials PLoS ONE 9 2014 e95354